<DOC>
	<DOCNO>NCT00245466</DOCNO>
	<brief_summary>To investigate long-term safety tolerability repeat dos degarelix prostate cancer patient</brief_summary>
	<brief_title>Study Investigating Long-Term Safety Tolerability Repeated Doses Degarelix Prostate Cancer Patients</brief_title>
	<detailed_description>Degarelix FDA regulate time trial . After completion trial degarelix approve FDA thus FDA regulate intervention ( FDA regulate intervention therefore tick `` YES '' ) . The data include participant main study ( FE200486 CS02 ; NCT00819247 ) extension study FE200486 CS02A .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Has complete study treatment study FE200486 CS02 . Has complete visit 16 study FE200486 CS02 . Has meet withdrawal criterion include visit 15 FE200486 CS02</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Androgen ablation therapy</keyword>
</DOC>